Compare Stocks → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BPTSNASDAQ:CALANASDAQ:KZIANASDAQ:PLXP Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPTSBiophytis$15.34$8.05▼$168.80$2.89M1.057,291 shs18,500 shsCALACalithera Biosciences$0.02$0.02$0.02▼$0.50$97KN/A796 shs330 shsKZIAKazia Therapeutics$0.29$0.30$0.19▼$1.39$4.67M2.07670,747 shs149,181 shsPLXPPLx Pharma$0.00$0.02▼$0.04$603K3.7912.96 million shs3,000 shs5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPTSBiophytis0.00%0.00%-50.77%-57.19%-93.68%CALACalithera Biosciences0.00%0.00%-33.55%-33.44%-25.93%KZIAKazia Therapeutics-0.48%+1.88%-37.43%+6.12%-78.36%PLXPPLx Pharma0.00%0.00%0.00%0.00%-97.89%Trump’s “Tax Free” Retirement Strategy (Ad)Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBPTSBiophytis2.3655 of 5 stars3.55.00.00.00.00.00.6CALACalithera BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AKZIAKazia Therapeutics0.2091 of 5 stars0.03.00.00.01.10.01.3PLXPPLx PharmaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBPTSBiophytis3.00Buy$600.00∞ UpsideCALACalithera BiosciencesN/AN/AN/AN/AKZIAKazia TherapeuticsN/AN/AN/AN/APLXPPLx PharmaN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBPTSBiophytisN/AN/AN/AN/A($17.29) per shareN/ACALACalithera Biosciences$9.75M0.01N/AN/A($0.40) per share-0.05KZIAKazia Therapeutics$20K233.68N/AN/A$0.50 per share0.57PLXPPLx Pharma$4.54M0.00N/AN/A$1.30 per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBPTSBiophytis-$18.43MN/A0.00N/AN/AN/AN/AN/AN/ACALACalithera Biosciences-$39.65MN/A0.00∞N/AN/AN/AN/AN/AKZIAKazia Therapeutics-$13.78MN/A0.00N/AN/AN/AN/AN/AN/APLXPPLx Pharma-$46.13M-$1.85N/AN/AN/A-606.91%-291.11%-119.43%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBPTSBiophytisN/AN/AN/AN/AN/ACALACalithera BiosciencesN/AN/AN/AN/AN/AKZIAKazia TherapeuticsN/AN/AN/AN/AN/APLXPPLx PharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBPTSBiophytisN/A0.720.72CALACalithera BiosciencesN/AN/AN/AKZIAKazia TherapeuticsN/A0.71N/APLXPPLx PharmaN/A4.794.28OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBPTSBiophytis0.05%CALACalithera BiosciencesN/AKZIAKazia Therapeutics30.89%PLXPPLx Pharma21.19%Insider OwnershipCompanyInsider OwnershipBPTSBiophytis3.70%CALACalithera Biosciences6.60%KZIAKazia Therapeutics1.00%PLXPPLx Pharma8.95%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBPTSBiophytis22351,000338,000Not OptionableCALACalithera Biosciences84.87 million4.55 millionNot OptionableKZIAKazia Therapeutics2,02116.34 million16.18 millionOptionablePLXPPLx Pharma1629.14 million26.53 millionNot OptionableBPTS, KZIA, PLXP, and CALA HeadlinesSourceHeadlineProtalix Biotherapeutics Inc (PLX)investing.com - January 30 at 9:00 AMVertex Pharmaceuticals Inc VRTXmorningstar.com - January 22 at 7:59 PMVietnam National Petroleum Group (PLX)investing.com - October 23 at 10:13 AMPLx Pharma Inc (PLXPQ)uk.investing.com - August 21 at 4:54 AMPharmaceutical R&D: the road to positive returnsnature.com - July 16 at 9:22 AMPLXPQ PLx Pharma Inc.seekingalpha.com - April 21 at 11:49 PMPLx Pharma Inc. Enters into a Stalking Horse Asset Purchase Agreement to Sell VAZALORE(R) and Substantially All of its Assetsmarketwatch.com - April 13 at 10:45 PMWhy PLx Pharma Shares Are Nosediving Todaymsn.com - April 12 at 4:03 PMWhy iMedia Brands Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarketmsn.com - April 12 at 10:33 AMWhy PLx Pharma Shares Are Down Over 40% Tuesdaymsn.com - April 11 at 11:47 PMPLx Pharma Inc. Receives Nasdaq Delisting Noticefinance.yahoo.com - April 11 at 6:43 PMShort Volatility Alert: Plx Pharma Incmsn.com - April 11 at 1:42 PMPLx Pharma's Return On Capital Employed Insightsmsn.com - December 22 at 2:37 PMPLx Pharma (PLXP) Q3 2022 Earnings Call Transcriptseekingalpha.com - November 11 at 11:44 AMPLx Pharma down after Q3 revenue fell 94% Y/Yseekingalpha.com - November 11 at 11:44 AMPLx Pharma Inc. Reports Third Quarter 2022 Results and Provides Business Updatefinance.yahoo.com - November 10 at 8:33 PMPLx Pharma, Inc. (PLXP) Reports Q3 Loss, Misses Revenue Estimatesfinance.yahoo.com - November 10 at 8:33 PMEarnings Preview: PLx Pharmamsn.com - November 10 at 3:32 PMPLx Pharma Inc. to Report Third Quarter 2022 Financial Results on November 11, 2022, and Provide Business Updatefinance.yahoo.com - October 26 at 12:57 PMBaseball Legend John Smoltz Featured on PLx Pharma’s Social Channelsfinance.yahoo.com - September 12 at 9:15 PMPLx Pharma Inc. (NASDAQ:PLXP) drops to US$21m and insiders who purchased earlier this year lose another US$52kfinance.yahoo.com - September 5 at 11:30 AMPLXP Aug 2022 5.000 callfinance.yahoo.com - August 20 at 9:18 PMPLx Pharma downgraded at Oppenheimer after Q2 missseekingalpha.com - August 15 at 2:42 PMPLx Pharma to Explore Strategic Alternatives, Reduces Teammarketwatch.com - August 12 at 11:28 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBiophytisNASDAQ:BPTSBiophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.Calithera BiosciencesNASDAQ:CALACalithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.Kazia TherapeuticsNASDAQ:KZIAKazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma. It is also developing EVT801, a small molecule targeted therapeutic vascular endothelial growth factor receptor 3 inhibitor. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.PLx PharmaNASDAQ:PLXPPLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of technology platform for approved drugs. It offers PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Sparta, NJ. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.